We are offering lopimune 200mg (lopinavir ).
Lopimune tablets 20050mg contain lopinavir and ritonavir, which are both inhibitors of hiv protease and are only effective against rna viruses (retroviruses) like human immunodeficiency virus (hiv). Retroviruses convert rna to dna, by the action of the viral-specific enzyme reverse transcriptase (rt). The viral dna is then integrated into the dna of infected immune cells so that the virus can replicate. Most of the antiviral activity of lopimune is due to lopinavir, which is a potent inhibitor of hiv protease, and prevents cleavage of the gag-pol polyprotein, an important protein in the development of active virus. The viral protease enzyme cleaves (breaks down) the gag-pol polyprotein during final stages of the replication cycle so that fully active mature virus can be released to infect new cells. Inhibition of protease cleavage by lopimune results in the production of immature, non-infectious viral particles. Ritonavir in lopimune tablets 20050mg is included in the combination not as a protease inhibitor but because it inhibits the cyp3a-mediated metabolism (breakdown in the liver) of lopinavir, thereby increasing the plasma levels of lopinavir so that lopinavir can be used at a lower dose. Lopimune tablets are used in combination with other retrovirals that have a different mechanism of action, like emtricitabine and tenofovir, both nucleoside reverse transcriptase inhibitor (nrti) that work by blocking the action of rt, inhibiting viral replication. The combined action of lopinavir and ritonavir in lopimune tablets 20050mg, in conjunction with other retroviral drugs, inhibits the production of active hiv so that the viral load (amount of virus) is reduced. Lopimune tablets slow down the replication of hiv within your body but does not kill the virus already incorporated in the cd4+ cells or prevent the spread of the infection to others.

We are offering lopimune 200mg (lopinavir ).
Lopimune tablets 20050mg contain lopinavir and ritonavir, which are both inhibitors of hiv protease and are only effective against rna viruses (retroviruses) like human immunodeficiency virus (hiv). Retroviruses convert rna to dna, by the action of the viral-specific enzyme reverse transcriptase (rt). The viral dna is then integrated into the dna of infected immune cells so that the virus can replicate. Most of the antiviral activity of lopimune is due to lopinavir, which is a potent inhibitor of hiv protease, and prevents cleavage of the gag-pol polyprotein, an important protein in the development of active virus. The viral protease enzyme cleaves (breaks down) the gag-pol polyprotein during final stages of the replication cycle so that fully active mature virus can be released to infect new cells. Inhibition of protease cleavage by lopimune results in the production of immature, non-infectious viral particles. Ritonavir in lopimune tablets 20050mg is included in the combination not as a protease inhibitor but because it inhibits the cyp3a-mediated metabolism (breakdown in the liver) of lopinavir, thereby increasing the plasma levels of lopinavir so that lopinavir can be used at a lower dose. Lopimune tablets are used in combination with other retrovirals that have a different mechanism of action, like emtricitabine and tenofovir, both nucleoside reverse transcriptase inhibitor (nrti) that work by blocking the action of rt, inhibiting viral replication. The combined action of lopinavir and ritonavir in lopimune tablets 20050mg, in conjunction with other retroviral drugs, inhibits the production of active hiv so that the viral load (amount of virus) is reduced. Lopimune tablets slow down the replication of hiv within your body but does not kill the virus already incorporated in the cd4+ cells or prevent the spread of the infection to others.